Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
BioAdaptives Inc.
- Market Cap
- Unavailable
- Price
- $0.00193
- % Change (Daily % change from the live per-ticker quote feed.)
- -28.52%
- Volume
- 16.3M
About
BioAdaptives, Inc. investigates, markets, and distributes natural plant, algal, and mushroom-based products and medical devices for humans and animals. It offers nutraceutical products, such as dietary supplements. The company offers Human Clinical trial; Zeranovia, a natural ingredient and uses proprietary methods of optimizing the availability of nutrients in foods and beverages; Lung Flute, a medical device; and Xcellara, PawPa, and MyndMed. The company was formerly known as APEX 8 Inc. and changed its name to BioAdaptives, Inc. in September 2013. The company was incorporated in 2013 and is based in Las Vegas, Nevada.
Quick stats
Shares outstanding—
Computed float9.8M
Float / sharesUnknown
Cash runway (months)-2.9
Key info
SectorConsumer Defensive
IndustryPackaged Foods
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001575142
AI Summary
AI-generated1/15
standardbullishrestructuring
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update
BioAdaptives CEO James Keener voluntarily canceled 43.25 million shares that were previously converted from preferred stock to common stock, effectively removing a long-term overhang to protect shareholder value.
The company also executed lock-up and leak-out agreements with major lenders to control share transaction flow and demonstrate institutional support for its growth strategy.
Management continues to be compensated exclusively in stock as the firm focuses on the commercial launch of its XcellaraHeart wellness formulation.
Red flags
- Management personnel are paid exclusively in stock with no cash salaries
- Public float liquidity was described as 'almost nonexistent' prior to restructuring